Use of dabigatran etexilate to reduce breast cancer progression

Cancer Biology and Therapy

Volumn 10, Issue 10, 2010, Pages 1001-1008

  DeFeo, Karen ^a   Hayes, Candace ^a   Chernick, Michael ^a   Van Ryn, Joanne ^b   Gilmour, Susan K ^a  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

4T1; Breast cancer; Coagulation; Metastasis; Thrombin inhibitor; Tumor invasion

Indexed keywords

DABIGATRAN ETEXILATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INVASION; CARCINOGENESIS; CARCINOGENICITY; CELL MIGRATION; CELL PROLIFERATION; DRUG EFFECT; MICROMETASTASIS; MOUSE; NONHUMAN; RAT; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTITHROMBIN PROTEINS; BENZIMIDAZOLES; BREAST NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CELLS, CULTURED; DISEASE PROGRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NIH 3T3 CELLS; PYRIDINES; RATS; THROMBIN; TRACHEA;

EID: 78549284650     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.10.13236     Document Type: Article

References (43)

1. Grand RJ, Turnell AS, Grabham PW. Cellular consequences of thrombin-receptor activation. Biochem J 1996; 313:353-68.
2. Rak J, Milsom C, May L, Klement P, Yu J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization and cancer coagulopathy. Semin Thromb Hemost 2006; 32:54-70.
3. Huntington JA. Molecular recognition mechanisms of thrombin. J Thromb Haemost 2005; 3:1861-72.
4. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407:258-64.
5. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3:1800-14.
6. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3:1894-904.
7. Hu L, Lee M, Campbell W, Perez-Soler R, Karpatkin S. Role of endogenous thrombin in tumor implantation, seeding and spontaneous metastasis. Blood 2004; 104:2746-51. (Pubitemid 39434957)
8. Nierodzik M, Karpatkin S. Hypercoagulability preceding cancer. Does hypercoagulability awaken dormant tumor cells in the host? J Thromb Haemost 2005; 3:577-80.
9. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000; 96:3302-9.
10. Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23:2123-9.
11. Sun NC, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol 1979; 71:10-6.
12. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23:2130-5.
13. Eriksson BI, Dahl OE. Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors. Drugs 2004; 64:577-95.
14. Antman EM. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994; 90:1624-30.
15. Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Laarman GJ, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med 1995; 333:757-63.
16. Eriksson BI, Dahl OE, Ahnfelt L, Kalebo P, Stangier J, Nehmiz G, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004; 2:1573-80. (Pubitemid 40186173)
17. Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3:103-11.
18. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002; 45:1757-66.
19. Terzaghi M, Nettesheim P, Williams ML. Repopulation of denuded tracheal grafts with normal, preneoplastic and neoplastic epithelial cell populations. Cancer Res 1978; 38:4546-53.
20. Momiki S, Baba M, Caa, Iizasa T, Nakajima M, Yamaguchi Y, et al. In vivo and In vitro invasiveness of human lung carcinoma cell lines. Invasion Metastasis 1991; 11.
21. Gilmour SK, Teti KA, Wu KQ, Morris RJ. A simple In Vivo System for studying epithelialization, hair, follicle formation and invasion using primary epidermal cells from wild-type and transgenic ornithine decarboxylase- overexpressing mouse skin. J Invest Dermatol 2001; 117:1674-6.
22. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67:6745-52.
23. Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45:555-63. (Pubitemid 40562946)
24. Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998; 4:909-14.
25. Heppner GH, Miller FR, Shekhar PM. Nontransgenic models of breast cancer. Breast Cancer Res 2000; 2:331-4.
26. Kershaw MH, Jackson JT, Haynes NM, Teng MW, Moeller M, Hayakawa Y, et al. Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. J Immunol 2004; 173:2143-50.
27. DuPre SA, Redelman D, Hunter KW Jr. The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci. Int J Exp Pathol 2007; 88:351-60. (Pubitemid 47416545)
28. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-51.
29. Nierodzik ML, Plotkin A, Kajumo F, Karpatkin S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest 1991; 87:229-36.
30. Wojtukiewicz MZ, Tang DG, Nelson KK, Walz DA, Diglio CA, Honn KV. Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta3 expression on the cell surface. Thromb Res 1992; 68:233-45.
31. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006; 10:355-62.
32. Nierodzik ML, Chen K, Takeshita K, Li JJ, Huang YQ, Feng XS, et al. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 1998; 92:3694-700.
33. Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004; 84:579-621.
34. Yang E, Boire A, Agarwal A, Nguyen N, O'Callaghan K, Tu P, et al. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res 2009; 69:6223-31.
35. Bachli EB, Pech CM, Johnson KM, Johnson DJ, Tuddenham EG, McVey JH. Factor Xa and thrombin, but not factor VIIa, elicit specific cellular responses in dermal fibroblasts. J Thromb Haemost 2003; 1:1935-44.
36. D'Andrea MR, Derian CK, Santulli RJ, Andrade-Gordon P. Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign and malignant human tissues. Am J Pathol 2001; 158:2031-41. (Pubitemid 32545189)
37. Niessen F, Schaffner F, Furlan-Freguia C, Pawlinski R, Bhattacharjee G, Chun J, et al. Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature 2008; 452:654-8.
38. Wang L, Luo J, He S. Induction of MMP-9 release from human dermal fibroblasts by thrombin: involvement of JAK/STAT3 signaling pathway in MMP-9 release. BMC Cell Biol 2007; 8:14.
39. Bogatkevich GS, Ludwicka-Bradley A, Silver RM. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis Rheum 2009; 60:3455-64.
40. Schulze EB, Hedley BD, Goodale D, Postenka CO, Al-Katib W, Tuck AB, et al. The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Res Treat 2008; 112:243-54.
41. Niers TM, Bruggemann LW, Klerk CP, Muller FJ, Buckle T, Reitsma PH, et al. Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung. Clin Exp Metastasis 2009; 26:171-8.
42. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 Breast Tumor Model. Current Protocols in Immunology: John Wiley & Sons, Inc 2000; 20:1-16.
43. Moase EH, Qi W, Ishida T, Gabos Z, Longenecker BM, Zimmermann GL, et al. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim Biophys Acta 2001; 1510:43-55. (Pubitemid 32149884)